{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:01:45Z","timestamp":1787767305968,"version":"build-2784847793"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.intimp.2022.109166","type":"journal-article","created":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T05:52:41Z","timestamp":1660888361000},"page":"109166","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Thymosin alpha 1 as an adjuvant to hyperthermic intraperitoneal chemotherapy in an experimental model of peritoneal metastases from colonic carcinoma"],"prefix":"10.1016","volume":"111","author":[{"given":"Nadav","family":"Nevo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Lee Goldstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoshi","family":"Bar-David","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Natanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilad","family":"Alon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Lahat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eran","family":"Nizri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.intimp.2022.109166_b0005","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1046\/j.1365-2168.2002.02274.x","article-title":"Peritoneal carcinomatosis from colorectal cancer","volume":"89","author":"Jayne","year":"2002","journal-title":"Br. J. Surg."},{"issue":"1","key":"10.1016\/j.intimp.2022.109166_b0010","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1200\/JCO.2009.23.9285","article-title":"Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study","volume":"28","author":"Elias","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.intimp.2022.109166_b0015","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/S1470-2045(16)30500-9","article-title":"Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database","volume":"17","author":"Franko","year":"2016","journal-title":"Lancet. Oncol."},{"key":"10.1016\/j.intimp.2022.109166_b0020","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.critrevonc.2016.01.017","article-title":"Progress in treatments for colorectal cancer peritoneal metastases during the years 2010\u20132015. A systematic review","volume":"100","author":"Baratti","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"2","key":"10.1016\/j.intimp.2022.109166_b0025","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S1470-2045(20)30599-4","article-title":"Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial","volume":"22","author":"Quenet","year":"2021","journal-title":"Lancet. Oncol."},{"issue":"11","key":"10.1016\/j.intimp.2022.109166_b0030","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1016\/j.ejso.2021.05.023","article-title":"The impact of PRODIGE 7 on the current worldwide practice of CRS-HIPEC for colorectal peritoneal metastases: A web-based survey and 2021 statement by Peritoneal Surface Oncology Group International (PSOGI)","volume":"47","author":"van de Vlasakker","year":"2021","journal-title":"Eur. J. Surg. Oncol."},{"issue":"11","key":"10.1016\/j.intimp.2022.109166_b0035","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/s41419-020-03221-2","article-title":"Detection of immunogenic cell death and its relevance for cancer therapy","volume":"11","author":"Fucikova","year":"2020","journal-title":"Cell. Death. Dis."},{"issue":"2","key":"10.1016\/j.intimp.2022.109166_b0040","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/onc.2015.82","article-title":"Hyperthermic intraperitoneal chemotherapy leads to an anticancer immune response via exposure of cell surface heat shock protein 90","volume":"35","author":"Zunino","year":"2016","journal-title":"Oncogene."},{"issue":"5","key":"10.1016\/j.intimp.2022.109166_b0045","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1245\/s10434-013-3061-z","article-title":"Consensus guidelines from The American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States","volume":"21","author":"Turaga","year":"2014","journal-title":"Ann. Surg. Oncol."},{"issue":"2","key":"10.1016\/j.intimp.2022.109166_b0050","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1073\/pnas.74.2.725","article-title":"Thymosin alpha1: isolation and sequence analysis of an immunologically active thymic polypeptide","volume":"74","author":"Goldstein","year":"1977","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.intimp.2022.109166_b0055","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.00873","article-title":"A Reappraisal of Thymosin Alpha1 in Cancer Therapy","volume":"9","author":"Costantini","year":"2019","journal-title":"Front. Oncol."},{"issue":"13\u201314","key":"10.1016\/j.intimp.2022.109166_b0060","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1016\/0959-8049(95)00477-7","article-title":"Sequential chemoimmunotherapy for advanced non-small cell lung cancer using cisplatin, etoposide, thymosin-alpha 1 and interferon-alpha 2a","volume":"31A","author":"Garaci","year":"1995","journal-title":"Eur. J. Cancer."},{"issue":"1","key":"10.1016\/j.intimp.2022.109166_b0065","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.bbrc.2015.06.132","article-title":"Thymosin alpha1 promotes the activation of myeloid-derived suppressor cells in a Lewis lung cancer model by upregulating Arginase 1","volume":"464","author":"Yuan","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"14","key":"10.1016\/j.intimp.2022.109166_b0070","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.3390\/cancers13143430","article-title":"Preclinical In Vivo-Models to Investigate HIPEC; Current Methodologies and Challenges","volume":"13","author":"Helderman","year":"2021","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.intimp.2022.109166_b0075","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/s002620050562","article-title":"Efficacy of repeated cycles of chemo-immunotherapy with thymosin alpha1 and interleukin-2 after intraperitoneal 5-fluorouracil delivery","volume":"48","author":"Silecchia","year":"1999","journal-title":"Cancer. Immunol. Immunother."},{"issue":"11","key":"10.1016\/j.intimp.2022.109166_b0080","doi-asserted-by":"crossref","first-page":"4232","DOI":"10.1182\/blood-2003-11-4036","article-title":"Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling","volume":"103","author":"Romani","year":"2004","journal-title":"Blood."},{"issue":"Suppl 1","key":"10.1016\/j.intimp.2022.109166_b0085","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1517\/14712598.2015.1008446","article-title":"Evaluation of thymosin alpha 1 in nonclinical models of the immune-suppressing indications melanoma and sepsis","volume":"15","author":"King","year":"2015","journal-title":"Expert. Opin. Biol. Ther."},{"issue":"2","key":"10.1016\/j.intimp.2022.109166_b0090","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1245\/s10434-017-6237-0","article-title":"T-Helper 1 Immune Response in Metastatic Lymph Nodes of Pancreatic Ductal Adenocarcinoma: A Marker For Prolonged Survival","volume":"25","author":"Nizri","year":"2018","journal-title":"Ann. Surg. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109166_b0095","doi-asserted-by":"crossref","first-page":"16878","DOI":"10.1038\/s41598-017-17204-5","article-title":"QuPath: Open source software for digital pathology image analysis","volume":"7","author":"Bankhead","year":"2017","journal-title":"Sci. Rep."},{"issue":"11","key":"10.1016\/j.intimp.2022.109166_b0100","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41568-020-0285-7","article-title":"The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy","volume":"20","author":"Bruni","year":"2020","journal-title":"Nat. Rev. Cancer."},{"key":"10.1016\/j.intimp.2022.109166_b0105","doi-asserted-by":"crossref","first-page":"669474","DOI":"10.3389\/fimmu.2021.669474","article-title":"Differentiation and Regulation of TH Cells: A Balancing Act for Cancer Immunotherapy","volume":"12","author":"Basu","year":"2021","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2022.109166_b0110","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nrclinonc.2017.194","article-title":"Perioperative events influence cancer recurrence risk after surgery","volume":"15","author":"Hiller","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.intimp.2022.109166_b0115","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/S1470-2045(20)30494-0","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial","volume":"21","author":"Ascierto","year":"2020","journal-title":"Lancet. Oncol."},{"issue":"5","key":"10.1016\/j.intimp.2022.109166_b0120","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S1470-2045(21)00065-6","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG\/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial","volume":"22","author":"Eggermont","year":"2021","journal-title":"Lancet. Oncol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922006506?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922006506?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:46:12Z","timestamp":1761587172000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576922006506"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":24,"alternative-id":["S1567576922006506"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2022.109166","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thymosin alpha 1 as an adjuvant to hyperthermic intraperitoneal chemotherapy in an experimental model of peritoneal metastases from colonic carcinoma","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2022.109166","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109166"}}